- Home
- RPRX vs NMR Comparison
RPRX vs NMR Comparison
Compare RPRX & NMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- NMR
- Stock Information
- Founded
- RPRX 1996
- NMR 1925
- Country
- RPRX United States
- NMR Japan
- Employees
- RPRX N/A
- NMR N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- NMR Investment Bankers/Brokers/Service
- Sector
- RPRX Health Care
- NMR Finance
- Exchange
- RPRX Nasdaq
- NMR Nasdaq
- Market Cap
- RPRX 14.2B
- NMR N/A
- IPO Year
- RPRX 2020
- NMR 1961
- Fundamental
- Price
- RPRX $31.13
- NMR $6.15
- Analyst Decision
- RPRX Strong Buy
- NMR Hold
- Analyst Count
- RPRX 5
- NMR 1
- Target Price
- RPRX $41.60
- NMR N/A
- AVG Volume (30 Days)
- RPRX 4.3M
- NMR 522.6K
- Earning Date
- RPRX 05-08-2025
- NMR 04-25-2025
- Dividend Yield
- RPRX 2.83%
- NMR 3.42%
- EPS Growth
- RPRX N/A
- NMR 184.58
- EPS
- RPRX 1.91
- NMR 0.67
- Revenue
- RPRX $2,263,576,000.00
- NMR $11,988,627,534.00
- Revenue This Year
- RPRX $33.46
- NMR $47.37
- Revenue Next Year
- RPRX $4.44
- NMR N/A
- P/E Ratio
- RPRX $16.28
- NMR $8.64
- Revenue Growth
- RPRX N/A
- NMR 30.73
- 52 Week Low
- RPRX $24.05
- NMR $4.66
- 52 Week High
- RPRX $34.20
- NMR $6.99
- Technical
- Relative Strength Index (RSI)
- RPRX 33.61
- NMR 45.76
- Support Level
- RPRX $32.26
- NMR $6.53
- Resistance Level
- RPRX $34.14
- NMR $6.67
- Average True Range (ATR)
- RPRX 0.76
- NMR 0.10
- MACD
- RPRX -0.33
- NMR 0.00
- Stochastic Oscillator
- RPRX 14.00
- NMR 50.85
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.